ArticleCureus2025
Targeted Acne Therapy Using Light-Absorbing Gold Microparticles Combined With Long-Pulsed 1064 nm Nd:YAG Laser: Case Series.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acne vulgaris is a prevalent dermatological disorder associated with inflammation and sebaceous gland hyperactivity. Conventional therapies, including topical and systemic agents, are limited by side effects, antimicrobial resistance, and frequent relapse. Light-absorbing gold microparticles activated by long-pulsed 1064 nm Nd:YAG laser therapy represent a novel, non-invasive approach targeting sebaceous glands. However, clinical data remain limited, particularly regarding optimal dosing. We report a series of four patients aged 19-31 years with moderate to severe acne vulgaris. Two patients received a low dose (1-2 cc), and two received a standard dose (2.5-3.5 cc) of gold microparticle suspension applied with sonophoresis, followed by 1500 shots of long-pulsed 1064 nm Nd:YAG laser. Each underwent three treatment sessions at two-week intervals. Clinical outcomes were assessed using standardized photography, Janus skin analyzer evaluation, and patient-reported satisfaction two weeks after the final session. Patients treated with the standard dose demonstrated marked reductions in inflammatory lesions, post-acne erythema, and skin oiliness, with high satisfaction and no recurrence during follow-up. In contrast, patients receiving the low dose showed only moderate improvement, with partial reduction in lesion counts and erythema. No adverse effects or complications were observed across all cases. This case series suggests that higher doses of gold microparticles combined with long-pulsed 1064 nm Nd:YAG laser therapy may provide superior clinical outcomes compared to lower doses in the management of moderate to severe acne vulgaris. Nonetheless, treatment with either dose was safe, well-tolerated, and associated with moderate-to-high patient satisfaction. Although encouraging, these findings are limited by a small sample size, and larger controlled studies with extended follow-up are needed to confirm efficacy and optimize treatment protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.